Clinical Trial Search

Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04

Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9

Primary: Transthoracic Echocardiogram (ECHO)-Based Change in the Tricuspid Annular Plane Systolic Excursion (TAPSE) Measurement — 2.244; 2.244; 2.300; 2.212 mm

Primary: Maximum Change From Baseline in Supine Systolic Blood Pressure (SBP) Within 4 Hours Post-dose at Visit 6 (Week 12) — -20.70; -20.20 mmHg

Primary: 6-minute-walk Distance (6MWD) — 330.0; 328.6 meters — p=0.7883

Primary: Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core — 27; 29; 3; 3 participants

Primary: Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16 — 18.567; -4.113 wood units*meter^2

Primary: Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks — 1.28 mL/min/kg

Primary: Change in Six-minute Walk Distance — 1.53; 9.45 meters

Primary: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 11; 8; 8; 2 participants

Primary: Plasma Estradiol (E2) Level — -40; -4 % change from baseline

Primary: Peak 6-minute Walk Distance — 366.0; 360.0; 21.6; 3.0 meters — p=0.00044

Primary: Change in Mean Pulmonary Artery Pressure (MPAP) — 6.5; 4.3 mmHg

Primary: Pulmonary Artery Systolic Pressure. — 58.6; 62.7; 42.8; 57.5 mmHg

Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC) — 35; -28; -21; 6 dyne*sec/cm^5 — p== 0.214

Primary: Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks — 382.94; 351.18 meters

Primary: Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population — 6.44; 13.40; 10.58; 10.24 percent change — p=0.056

Primary: Left Ventricular End Diastolic Volume — 81; 70 ml

Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) — 514.6; 512.0 dyn*sec/cm^5 — p=0.0220

Primary: Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks — -27.6; -168.4; -258.9; 802.0 dynes*sec/cm^5 — p=0.0030

Primary: Change From Baseline in Six Minute Walk Distance (Meters) — 414.5; 461.7; 448.9; 483.0 meters

Primary: Changes From Baseline in Peak Exercise Mean Pulmonary Artery Pressure (mPAP), Transpulmonary Pressure Gradient (TPG), and Pulmonary Capillary Wedge Pressure (PCWP)…

Primary: Absolute Change in Right Ventricular Ejection Fraction — 10.4 % RVEF — p=0.028

Primary: Pulmonary Vascular Resistance (PVR) — 6.7 woods unit

Primary: Change in Pulmonary Vascular Resistance (PVR) — 0.77; 0.40; -0.39 Woods units — p=0.002

Primary: Number of Patients Reaching a 6-Minute Walk Test (6MWT) Distance ≥ 380 Meters — 16; 24 participants

Primary: Change in Exercise Pulmonary Hemodynamics From Baseline to Week 24 — 37.4 mmHg — p=.0008

Primary: 6-minute Walk Distance (6MWD) — 370; 365; 15; 11 meters — p=0.089

Primary: Changes in Right Ventricular Ejection Fraction (RVEF %) After 3 Months Intervention — -2.8; 3.9 percentage of ejected blood — p=0.008

Primary: Change in 6 Minute Walk Test — 7.00; 16.60; 16.00; 4.90 Meters walked in 6 minutes